SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

Elfabrio

PLX·Protalix BioTherapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. FDA approved May 2023, EU approved (initial regimen), with the every-four-weeks EU dosing regimen approved March 2026.
Why 4/10
Elfabrio is already approved and commercialized in the US and EU with no pending PDUFA or pivotal readout for this drug. The next hard catalyst for Elfabrio itself would be a potential US filing for every-four-weeks dosing, but no submission date has been announced. The stock's next major binary catalyst is PRX-115 Phase 2 topline data in H2 2027, which is a separate pipeline asset. As an approved, marketed drug with commercial execution as the primary driver, Elfabrio scores a 4.
Actionable Insight NEUTRAL

Elfabrio is an approved, revenue-generating drug with growing sales, but the stock's next major binary catalyst is the separate PRX-115 Phase 2 gout readout in H2 2027. For Elfabrio specifically, watch quarterly revenue trends and any announcement of a US filing for the every-four-weeks dosing regimen, which would be a positive catalyst. The Q4 2026 earnings (expected early 2027) will provide the next update on commercial traction.

Price Chart

Loading chart...

Executive Summary

Elfabrio (pegunigalsidase alfa) is a PEGylated enzyme replacement therapy for Fabry disease, approved in the US (May 2023), EU, and Canada. It is developed by Protalix BioTherapeutics (PLX) and commercialized by partner Chiesi Global Rare Diseases. The drug competes against Sanofi's Fabrazyme and BioMarin's oral Galafold. Protalix reported strong Q3 2026 results with $21.9M total revenue and $4.0M net income, beating estimates, and management sees a $3.2B Fabry market by 2031 targeting 15-20% market share. The EU approval of every-four-weeks dosing (March 2026) is a competitive differentiator. However, the drug faces headwinds from oral competition (Galafold) and new entrants, and the stock's next major binary catalyst is the separate PRX-115 gout program in H2 2027, not Elfabrio itself.

How It Works

Elfabrio is an enzyme replacement therapy (ERT) for Fabry disease, a rare genetic disorder. Patients with Fabry disease lack a working enzyme called alpha-galactosidase A, causing harmful fats to build up in cells. Elfabrio is a lab-made version of that enzyme, modified with a PEG coating (a common technique to help the drug last longer in the body and reduce immune reactions). It is given as an intravenous infusion every two weeks (or every four weeks for stable patients in the EU) to replace the missing enzyme and clear the fatty buildup.

Trial Status

Elfabrio was approved by the FDA in May 2023 and by the European Commission (initial approval, then an additional every-four-weeks dosing regimen approved March 2026). Health Canada approved it in December 2025. Two Phase 3 open-label extension studies have completed: one for the 1 mg/kg every-2-weeks regimen (97 patients, completed January 2025) and one for the 2 mg/kg every-4-weeks regimen (29 patients, completed April 2026). The Phase 3 BRIGHT study results were published in October 2024.

The Two-Sided Case

▲ Bull Case5
Elfabrio revenue is growing rapidly: Protalix reported Q3 2026 total revenue of $21.9M (beating ~$12M consensus) and $75.6M year-to-date, up from $43.6M in the prior-year period, with net income of $4.0M for the quarter.
The EU approval of every-four-weeks dosing (March 2026) is a competitive advantage that could drive market share gains by reducing infusion burden for stable patients, and triggered a $25M milestone payment from Chiesi.
Management targets 15-20% of the Fabry market by 2031 in a projected $3.2B total addressable market, which would imply meaningful Elfabrio-related revenue growth and royalty streams for Protalix.
Analyst consensus is bullish: 4 Buy/Strong Buy vs 1 Hold, with a mean price target of $11 (roughly 3x the current ~$2.86 price), and HC Wainwright has a Buy rating with top-tier accuracy on the name.
Institutional accumulation is evident: Goldman Sachs, Dimensional Fund Advisors, JPMorgan, and others added or doubled positions in Q2/Q3 2026.
▼ Bear Case5
Elfabrio faces strong competition from Sanofi's well-established Fabrazyme (agalsidase beta) ERT and BioMarin's oral Galafold (migalastat), which is more convenient for the subset of patients with amenable mutations and may limit Elfabrio's addressable population.
BioMarin inked a deal in October 2026 to license another Fabry candidate, signaling potential future competition that could pressure Elfabrio's market share before it reaches peak sales.
The every-four-weeks dosing regimen is approved only in the EU, not the US, limiting its competitive differentiation in the larger US market.
Seeking Alpha analysis from April 2026 titled 'Elfabrio Struggles Against Oral Competition' noted that the partnership structure with Chiesi means Protalix's revenue from Elfabrio is not fully reflective of end-market sales, and the company's revenue can vary quarter-to-quarter based on partner ordering timing.
The stock's next major binary catalyst is PRX-115 (gout) topline data in H2 2027, not Elfabrio, meaning near-term share price may lack a clear catalyst-driven trigger.

Upcoming Catalysts

  • Q4 2026 / full-year 2026 earnings report (early 2027) showing Elfabrio revenue trajectory
  • Potential US FDA filing for every-four-weeks dosing regimen (not yet submitted per March 2026 press release)
  • PRX-115 Phase 2 topline data for uncontrolled gout expected H2 2027 (separate pipeline asset)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report

Sources · 10

Hover a chip for the title
1 nasdaq.com2 healio.com3 prnewswire.com4 seekingalpha.com5 seekingalpha.com6 rttnews.com7 victoriaadvocate.com8 fiercebiotech.com9 sec.gov10 seekingalpha.com